Point72 Asset Management
XENE icon

Point72 Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Point72 Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,300
Closed -$541K – 4648
2026
Q1 		$541K Hold
9,300
– – ﹤0.01% 3084
2025
Q4 		$417K Buy
+9,300
New +$391K ﹤0.01% 3327

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Point72 Asset Management's XENE Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 130,378 shares worth $7.87M. The stake represents 0.01% of the portfolio and ranks #1438 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in XENE as recently as Q1 2025.

Point72 Asset Management first reported a position in XENE in Q1 2015 and has held it in 41 quarters since. The position peaked at $93.5M in Q4 2021. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Point72 Asset Management held 130,378 shares of Xenon Pharmaceuticals worth $7.87M as of Q2 2026.
  • Xenon Pharmaceuticals was a new Point72 Asset Management position in Q2 2026.
  • Xenon Pharmaceuticals made up 0.01% of Point72 Asset Management's portfolio in Q2 2026, its #1438 holding.
  • Point72 Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2015 and has held it in 41 quarters since.
  • Point72 Asset Management's Xenon Pharmaceuticals position peaked at $93.5M in Q4 2021.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.